Phase 2 trial of VG081821 to ease motor symptoms fully enrolled
Enrollment is complete in a Phase 2 trial of VG081821, an investigational therapy to treat early to mid-stage Parkinson’s…
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Enrollment is complete in a Phase 2 trial of VG081821, an investigational therapy to treat early to mid-stage Parkinson’s…
Ryan Reynolds is the face of an educational campaign aiming to raise awareness of lesser-known Parkinson’s disease symptoms: the…
Sensor-equipped shoes — called NUSHU smart shoes — that are designed to support people with walking difficulties due to…
Photopharmics said the first 100 patients have been enrolled in a Phase 3 trial testing its light-based therapy device,…
The U.S. Food and Drug Administration (FDA) has approved Medtronic’s Asleep Deep Brain Stimulation (DBS) surgery for people…
Merck‘s U.S. and Canada life sciences business, MilliporeSigma, signed a memorandum of understanding with Gene Therapy Research Institution (GTRI),…
Nearly one-quarter of deceased athletes with chronic traumatic encephalopathy (CTE), a neurodegenerative disease associated with repetitive head impacts, experienced…
Brenig Therapeutics has raised $65 million to advance its lead candidate, LRRK inhibitor BT-267, into human clinical trials as…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $6 million grant to Lario…
Scientists have discovered a link between a mutation in the CARS gene and late-onset neurological disorders with symptoms, such…
Get regular updates to your inbox.